NuVasive Gains Clearance for Expanded Use of Attrax Putty

By Julie A. Vetalice

NuVasive Gains Clearance for Expanded Use of Attrax Putty

NuVasive received FDA 510(k) clearance for expanded indications of use for Attrax® Putty with its thoracolumbar interbody portfolio for spine surgery. Attrax Putty is reportedly the first synthetic biologic to receive indications for use in interbody fusion of the thoracolumbar spine.

Attrax Putty is a synthetic, bioactive and osteoconductive bone void filler designed to drive bone fusion. This proprietary biomaterial features a surface microarchitecture designed to provide an optimized environment for bone formation without added cells or growth factors. Attrax Putty is supported by a Level I randomized controlled trial as a bone graft substitute in posterolateral spinal fusions. Recent studies have demonstrated that Attrax Putty performs comparably to autograft bone in thoracolumbar interbody fusion.

With this clearance, Attrax Putty can now be used with NuVasive's procedurally integrated thoracolumbar interbody portfolio that includes the Advanced Materials Science™ technologies of Modulus® porous titanium and Cohere® Porous PEEK™.

Source: NuVasive

Product Labels: Lumbar Spine, Spinal Fusion

Tags: 510(k) Clearance, Regulatory